These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26320495)

  • 1. Drug Use Evaluation of Letrozole in Breast Cancer Patients at Regional Cancer Hospitals in Thailand.
    Ketkaew C; Kiatying-Angsulee N
    Asian Pac J Cancer Prev; 2015; 16(14):6055-9. PubMed ID: 26320495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
    Lipsitz M; Delea TE; Guo A
    Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
    Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
    Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
    Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
    Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
    Bedard PL; Singhal SK; Ignatiadis M; Bradbury I; Haibe-Kains B; Desmedt C; Loi S; Evans DB; Michiels S; Dixon JM; Miller WR; Piccart MJ; Sotiriou C
    Endocr Relat Cancer; 2011 Dec; 18(6):721-30. PubMed ID: 21984694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
    Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
    Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
    Bertelli G; Garrone O; Bertolotti L; Occelli M; Conforti S; Marzano N; Febbraro A; Carlini P; Liossi C; Del Mastro L; Leonard RC
    Oncology; 2005; 68(4-6):364-70. PubMed ID: 16020964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
    Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
    J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.
    McArthur HL; Gelmon KA; Olivotto IA; Speers CH; Ellard SL; O'Reilly SE; Kennecke HF
    J Clin Oncol; 2009 Mar; 27(9):1388-93. PubMed ID: 19237634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA; Lebwohl D
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
    Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
    J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
    Huober J; Fasching PA; Barsoum M; Petruzelka L; Wallwiener D; Thomssen C; Reimer T; Paepke S; Azim HA; Ragosch V; Kubista E; Baumgärtner AK; Beckmann MW; May C; Nimmrich I; Harbeck N
    Breast; 2012 Feb; 21(1):27-33. PubMed ID: 21862331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.
    Nuijten M; Meester L; Waibel F; Wait S
    Pharmacoeconomics; 1999 Oct; 16(4):379-97. PubMed ID: 10623366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.